Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog

Order Display Name: Geisinger Epic Procedure Code Or ID CPT Code:  

EBV EARLY ANTIGEN IGG ANTIBODY

ORDERING INFORMATION:
Geisinger Epic Procedure Code: LAB2229         Geisinger Epic ID: 32952

SPECIMEN COLLECTION
Specimen type:
Serum
Preferred collection container:
Alternate Collection Container:
6 mL red-top (plain, non-serum separator) tube
Specimen required:
0.5 mL serum. Minimum 0.2 mL.

SPECIMEN PROCESSING
Specimen processing instructions:
Allow to clot. Centrifuge and submit 0.5 mL serum. 
Transport temperature:
Refrigerated (preferred). Room temperature (stable 8 hours) and frozen specimens also acceptable.
Specimen stability:
Room temperature: 8 hours; 2-8ÂșC: 96 hours. Frozen: 6 months.
Rejection criteria:
Specimen stability exceeded; specimen grossly hemolyzed.

TEST DETAILS
Interpretation guide:
Result
Interpretation
Negative Absence of detectable EA IgG antibodies. A negative result generally excludes exposure to Epstein-Barr virus, but may also be associated with past infection.
Equivocal If exposure to Epstein-Barr is suspected despite an initial equivocal finding, a second sample should be collected and tested one to two weeks later.
Positive Presence of detectable EA IgG antibodies. A positive result indicates exposure to Epstein-Barr virus and is usually associated with active or recent primary (acute) infection or reactivation.

This test is for the qualitative determination of IgG antibodies to EBV early antigen.

CPT code(s):
86663
Note: The billing party has sole responsibility for CPT coding.  Any questions regarding coding should be directed to the payer being billed.  The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.
Test includes:
Antibody detection to EBV Early Antigen IgG.
Methodology:
Chemiluminescence
Synonyms:
EBV Early Antigen-Diffuse
EBV EA-D
EBVEAR
Clinical significance:
Epstein-Barr virus (EBV) is responsible for infectious mononucleosis (IM) and has also been implicated in Burkitt's lymphoma and nasopharyngeal carcinoma. EBV-EA (Epstein-Barr virus early antigen) IgG antibodies are associated with primary (acute) stage of EBV infection and are generally undetectable six months after clinical onset of the disease. A negative result does not rule out current EBV infection, and a positive result should be substantiated with an EBV-IgM test.
Doctoral Director(s:)
Hoi-Ying Elsie Yu, PhD, DABCC
Stacy Kenyon, PhD, DABCC
   
Review Date: 12/02/2020

Performing Locations

Geisinger Medical Center

Performing laboratory: Immunology
Technical Lead: Kathy Hurst
Frequency: Five days per week, 1st shift.
Performed stat? No
Locations  |    Search  |    Site Map |   Contact Us
©2000-2021 Geisinger Health System.   All rights reserved.